Design of iron chelators with therapeutic application
The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Iron is essential for the proper functioning of all living cells, however it is toxic when present in excess. Thus, using iron chelators as therapeutic agents, namely chelation therapy, has received increasing attention. The objective of this review is to discuss the factors which should be considered when designing clinically useful iron chelators, to present the application of iron chelators in the treatment of iron overload associated with β-thalassaemia major and sickle cell anaemia, and to highlight the potential applications in the treatment of neurodegenerative disorders and microbial infection. This article reviews recent knowledge centred on these themes and indicates the growing importance of the concept of iron chelation in medicine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An effective iron chelator must be nontoxic, must have higher affinity for ferric iron than bacterial siderophores and must not be recognized by microbial siderophore transporters94.”
From Iron homeostasis in host defence and inflammation (2015) · cites this paper as [94]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Chemistry and biology of siderophores
Hider, R. C., & Kong, X. (2010) · Natural Product Reports · doi:10.1039/b906679a · Cited by 1,722
Self-citationRae, T. D., Schmidt, P. J., Pufahl, R. A., Culotta, V. C., & V. O'Halloran, T. (1999) · Science · doi:10.1126/science.284.5415.805 · Cited by 1,629
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Weinberg, E. D. (1978) · Microbiological Reviews · doi:10.1128/mmbr.42.1.45-66.1978 · Cited by 1,254
Protective effects of the sickle cell gene against malaria morbidity and mortality
Aidoo, M., Terlouw, D. J., Kolczak, M. S., McElroy, P. D., ter Kuile, F. O., Kariuki, S., Nahlen, B. L., Lal, A. A., & Udhayakumar, V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08273-9 · Cited by 700
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Pardridge, W. M., Boado, R. J., & Farrell, C. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)38267-x · Cited by 606
Rational Design of Sequestering Agents for Plutonium and Other Actinides
Gorden, A. E. V., Xu, J., Raymond, K. N., & Durbin, P. (2003) · Chemical Reviews · doi:10.1021/cr990114x · Cited by 552
Pennell, D. J. (2006) · Blood · doi:10.1182/blood-2005-07-2948 · Cited by 495
Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in a Biofilm
Banin, E., Brady, K. M., & Greenberg, E. P. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.72.3.2064-2069.2006 · Cited by 473
Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
Olivieri, N. F., Buncic, J. R., Chew, E., Gallant, T., Harrison, R. V., Keenan, N., Logan, W., Mitchell, D., Ricci, G., Skarf, B., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198604033141402 · Cited by 429
IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA
Pippard, M. J., Warner, G. T., Callender, S. T., & Weatherall, D. J. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92175-5 · Cited by 419
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Gaeta, A., & Hider, R. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706416 · Cited by 411
Self-citationSelective iron chelation in Friedreich ataxia: biologic and clinical implications
Boddaert, N., Le Quan Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.-C., Munnich, A., & Cabantchik, Z. I. (2007) · Blood · doi:10.1182/blood-2006-12-065433 · Cited by 409
Lipid solubility and drug penetration of the blood brain barrier
Oldendorf, W. H. (1974) · Experimental Biology and Medicine · doi:10.3181/00379727-147-38444 · Cited by 373
Scott, L. E., & Orvig, C. (2009) · Chemical Reviews · doi:10.1021/cr9000176 · Cited by 332
The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308
Coordination chemistry and microbial iron transport
Raymond, K. N., & Carrano, C. J. (1979) · Accounts of Chemical Research · doi:10.1021/ar50137a004 · Cited by 292
Cappellini, M. D., Porter, J., El-Beshlawy, A., Li, C. K., Seymour, J. F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J. W., Chan, L. L., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.014696 · Cited by 288
Siderophores as drug delivery agents: application of the “Trojan Horse” strategy
Möllmann, U., Heinisch, L., Bauernfeind, A., Köhler, T., & Ankel-Fuchs, D. (2009) · BioMetals · doi:10.1007/s10534-009-9219-2 · Cited by 274
Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06455.x · Cited by 271
Design of clinically useful iron(III)‐selective chelators
Liu, Z. D., & Hider, R. C. (2002) · Medicinal Research Reviews · doi:10.1002/med.1027 · Cited by 266
Self-citationIron(iii) citrate speciation in aqueous solution
Silva, A. M. N., Kong, X., Parkin, M. C., Cammack, R., & Hider, R. C. (2009) · Dalton Transactions · doi:10.1039/b910970f · Cited by 261
Self-citationShachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246
Role of deferiprone in chelation therapy for transfusional iron overload
Hoffbrand, A. V., Cohen, A., & Hershko, C. (2003) · Blood · doi:10.1182/blood-2002-06-1867 · Cited by 244
Treatment of Alzheimer’s Disease with Clioquinol
Regland, B., Lehmann, W., Abedini, I., Blennow, K., Jonsson, M., Karlsson, I., Sjögren, M., Wallin, A., Xilinas, M., & Gottfries, C.-G. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051288 · Cited by 220
Combined therapy with deferiprone and desferrioxamine
Wonke, Wright, & Hoffbrand (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01002.x · Cited by 218
The safety and effectiveness of deferiprone in a large‐scale, 3‐year study in Italian patients
Ceci, A., Baiardi, P., Felisi, M., Cappellini, M. D., Carnelli, V., De Sanctis, V., Galanello, R., Maggio, A., Masera, G., Piga, A., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03554.x · Cited by 215
Current Status of Metals as Therapeutic Targets in Alzheimer's Disease
Finefrock, A. E., Bush, A. I., & Doraiswamy, P. M. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51368.x · Cited by 204
Glickstein, H., El, R. B., Link, G., Breuer, W., Konijn, A. M., Hershko, C., Nick, H., & Cabantchik, Z. I. (2006) · Blood · doi:10.1182/blood-2006-05-020867 · Cited by 201
Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial
Maggio, A., D'Amico, G., Morabito, A., Capra, M., Ciaccio, C., Cianciulli, P., Di Gregorio, F., Garozzo, G., Malizia, R., Magnano, C., et al. (2002) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.2002.0510 · Cited by 192
Kontoghiorghes, G. J., Aldouri, M. A., Hoffbrand, A. V., Barr, J., Wonke, B., Kourouclaris, T., & Sheppard, L. (1987) · BMJ · doi:10.1136/bmj.295.6612.1509 · Cited by 187
Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron‐Loaded Subjects
Summers, M. R., Jacobs, A., Tudway, D., Perera, P., & Ricketts, C. (1979) · British Journal of Haematology · doi:10.1111/j.1365-2141.1979.tb01167.x · Cited by 179
Complex Formation of ICL670 and Related Ligands with FeIII and FeII
Steinhauser, S., Heinz, U., Bartholomä, M., Weyhermüller, T., Nick, H., & Hegetschweiler, K. (2004) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200400363 · Cited by 173
Rival, T., Page, R. M., Chandraratna, D. S., Sendall, T. J., Ryder, E., Liu, B., Lewis, H., Rosahl, T., Hider, R., Camargo, L. M., et al. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06701.x · Cited by 170
Self-citationGalanello, R., Piga, A. G., Alberti, D., Rouan, M. C., Bigler, H., & Séchaud, R. (2003) · PubMed · Cited by 169
Facilitation of Fe(II) antoxidation by Fe(III) complexing agents
Harris, D. C., & Aisen, P. (1973) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(73)90019-6 · Cited by 168
Iron Chelators for Thalassaemia
Hershko, C., Konijn, A. M., & Link, G. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00726.x · Cited by 160
Eplattenier, F. L., Murase, I., & Martell, A. E. (1967) · Journal of the American Chemical Society · doi:10.1021/ja00980a019 · Cited by 157
NEUROLOGICAL SYNDROME ASSOCIATED WITH CLIOQUINOL
Tsubaki, T., Honma, Y., & Hoshi, M. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92699-7 · Cited by 154
Hershko, C., Konijn, A. M., Nick, H. P., Breuer, W., Cabantchik, Z. I., & Link, G. (2001) · Blood · doi:10.1182/blood.v97.4.1115 · Cited by 151
Porter, J. B., Jaswon, M. S., Huehns, E. R., East, C. A., & Hazell, J. W. P. (1989) · British Journal of Haematology · doi:10.1111/j.1365-2141.1989.tb07761.x · Cited by 151
Balfour, J. A. B., & Foster, R. H. (1999) · Drugs · doi:10.2165/00003495-199958030-00021 · Cited by 146
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores
Wood, J. C., Kang, B. P. S., Thompson, A. A., Giardina, P. J., Harmatz, P., Glynos, T., Paley, C. S., & Coates, T. D. (2010) · Blood · doi:10.1182/blood-2009-11-250308 · Cited by 145
Galanello, R., Piga, A., Alberti, D., Rouan, M.-C., Bigler, H., & Séchaud, R. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043006002 · Cited by 141
Meiwes, J., Fiedler, H.-P., Haag, H., Zähner, H., Konetschny-Rapp, S., & Jung, G. (1990) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1990.tb13863.x · Cited by 140
Dexter, D. T., Statton, S. A., Whitmore, C. L., Freinbichler, W., Weinberger, P., Tipton, K. F., Corte, L., Ward, R. J., & Crichton, R. R. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0531-3 · Cited by 139
Enkephalin Glycopeptide Analogues Produce Analgesia with Reduced Dependence Liability
Bilsky, E. J., Egleton, R. D., Mitchell, S. A., Palian, M. M., Davis, P., Huber, J. D., Jones, H., Yamamura, H. I., Janders, J., Davis, T. P., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000077y · Cited by 133
Iron and citric acid: A fuzzy chemistry of ubiquitous biological relevance
Pierre, J., & Gautier‐Luneau, I. (2000) · BioMetals · doi:10.1023/a:1009225701332 · Cited by 132
Heinz, U., Hegetschweiler, Κ., Acklin, P., Faller, B., Lattmann, R., & Schnebli, H. P. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990903)38:17<2588::aid-anie2588>3.0.co;2-8 · Cited by 131
Strouse, J., Layten, S. W., & Strouse, C. E. (1977) · Journal of the American Chemical Society · doi:10.1021/ja00444a041 · Cited by 129
Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation
Kakhlon, O., Manning, H., Breuer, W., Melamed-Book, N., Lu, C., Cortopassi, G., Munnich, A., & Cabantchik, Z. I. (2008) · Blood · doi:10.1182/blood-2008-06-161919 · Cited by 129
Chelation therapy in [beta ]-thalassemia: An optimistic update
Giardina, P. J., & Grady, R. W. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90030-7 · Cited by 129
Heinz, U., Hegetschweiler, K., Acklin, P., Faller, B., Lattmann, R., & Schnebli, H. P. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990903)38:17<2568::aid-anie2568>3.0.co;2-c · Cited by 128
Rodgers, S. J., Lee, C. W., Ng, C. Y., & Raymond, K. N. (1987) · Inorganic Chemistry · doi:10.1021/ic00257a030 · Cited by 127
Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S. (2008) · The FASEB Journal · doi:10.1096/fj.07-8627rev · Cited by 126
Rhizoferrin: A complexone type siderophore of the mocorales and entomophthorales (Zygomycetes)
Thieken, A. (1992) · FEMS Microbiology Letters · doi:10.1016/0378-1097(92)90579-d · Cited by 126
Miller, M. J., & Malouin, F. (1993) · Accounts of Chemical Research · doi:10.1021/ar00029a003 · Cited by 125
Silva, A. M. N., Kong, X., & Hider, R. C. (2009) · BioMetals · doi:10.1007/s10534-009-9224-5 · Cited by 121
Self-citationNurchi, V. M., Crisponi, G., Pivetta, T., Donatoni, M., & Remelli, M. (2007) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.10.012 · Cited by 103
Harris, W. H., & Raymond, K. N. (1979) · Journal of the American Chemical Society · doi:10.1021/ja00516a011 · Cited by 101
Porter, J., Morgan, J., Hoyes, K., Burke, L., Huehns, E., & Hider, R. (1990) · Blood · doi:10.1182/blood.v76.11.2389.2389 · Cited by 100
Self-citationA Risk-Benefit Assessment of Iron-Chelation Therapy
Porter, J. B. (1997) · Drug Safety · doi:10.2165/00002018-199717060-00006 · Cited by 95
Preston, J. E., Al‐Sarraf, H., & Segal, M. B. (1995) · Developmental Brain Research · doi:10.1016/0165-3806(95)00060-q · Cited by 94
Fredenburg, A. M., Sethi, R. K., Allen, D. D., & Yokel, R. A. (1996) · Toxicology · doi:10.1016/0300-483x(95)03301-u · Cited by 94
Hider, R. C., Mohd-Nor, A. R., Silver, J., Morrison, I. E. G., & Rees, L. V. C. (1981) · J. Chem. Soc., Dalton Trans. · doi:10.1039/dt9810000609 · Cited by 93
Self-citationLiu, Z. D., Khodr, H. H., Liu, D. Y., Lu, S. L., & Hider, R. C. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm991080o · Cited by 88
Self-citationShin, R., Kruck, T. P. A., Murayama, H., & Kitamoto, T. (2003) · Brain Research · doi:10.1016/s0006-8993(02)03893-3 · Cited by 88
FAGERHOLM, NILSSON, KNUTSON, & LENNERNÄS (1999) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.1999.00510.x · Cited by 85
Evaluation of desferrithiocin and its synthetic analogs as orally effective iron chelators
Bergeron, R. J., Wiegand, J., Dionis, J. B., Egli-Karmakka, M., Frei, J., Huxley-Tencer, A., & Peter, H. H. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00111a023 · Cited by 84
The potential application of iron chelators for the treatment of neurodegenerative diseases
Hider, R. C., Roy, S., Ma, Y. M., Le Kong, X., & Preston, J. (2011) · Metallomics · doi:10.1039/c0mt00087f · Cited by 83
Self-citationNeuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells
Molina‐Holgado, F., Gaeta, A., Francis, P. T., Williams, R. J., & Hider, R. C. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05332.x · Cited by 82
Self-citationForni, G. L., Balocco, M., Cremonesi, L., Abbruzzese, G., Parodi, R. C., & Marchese, R. (2008) · Movement Disorders · doi:10.1002/mds.22002 · Cited by 80
Silva, A. M. N., & Hider, R. C. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.06.003 · Cited by 79
Self-citationBattaglia, G., Russa, M. F. L., Bruno, V., Arenare, L., Ippolito, R., Copani, A., Bonina, F. P., & Nicoletti, F. (2000) · Brain Research · doi:10.1016/s0006-8993(00)01962-4 · Cited by 77
Fanconi Syndrome Due to Deferasirox
Rafat, C., Fakhouri, F., Ribeil, J., Delarue, R., & Quintrec, M. L. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.013 · Cited by 76
Serratrice, G., Boukhalfa, H., Béguin, C., Baret, P., Caris, C., & Pierre, J.-L. (1997) · Inorganic Chemistry · doi:10.1021/ic9608096 · Cited by 75
Bergeron, R., Streiff, R., Wiegand, J., Luchetta, G., Creary, E., & Peter, H. (1992) · Blood · doi:10.1182/blood.v79.7.1882.1882 · Cited by 75
Combined iron chelation therapy
Galanello, R., Agus, A., Campus, S., Danjou, F., Giardina, P. J., & Grady, R. W. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05591.x · Cited by 75
Iron chelation using subcutaneous infusions of diethylene triamine penta‐acetic acid (DTPA)
Pippard, M. J., Jackson, M. J., Hoffman, K., Petrou, M., & Modell, C. B. (1986) · Scandinavian Journal of Haematology · doi:10.1111/j.1600-0609.1986.tb02282.x · Cited by 73
Evans, P., Kayyali, R., Hider, R. C., Eccleston, J., & Porter, J. B. (2010) · Translational Research · doi:10.1016/j.trsl.2010.05.002 · Cited by 72
Self-citationSingh, S., Epemolu, R. O., Dobbin, P. S., Tilbrook, G. S., Ellis, B. L., Damani, L. A., & Hider, R. C. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08575-7 · Cited by 72
Self-citationFernández, C. I., Nieto, O., Rivas, E., Montenegro, G. Y., Fontenla, J. A., & Fernández‐Mayoralas, A. (2000) · Carbohydrate Research · doi:10.1016/s0008-6215(00)00073-2 · Cited by 72
Maggio, A., Vitrano, A., Capra, M., Cuccia, L., Gagliardotto, F., Filosa, A., Romeo, M. A., Magnano, C., Caruso, V., Argento, C., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07609.x · Cited by 71
Abeysinghe, R. D., Roberts, P. J., Cooper, C. E., MacLean, K. H., Hider, R. C., & Porter, J. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.7965 · Cited by 70
Self-citationIn vitro inhibition of bacterial growth by iron chelators
Qiu, D.-H., Huang, Z.-L., Zhou, T., Shen, C., & Hider, R. C. (2011) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02153.x · Cited by 70
Self-citationLiu, Z. D., Kayyali, R., Hider, R. C., Porter, J. B., & Theobald, A. E. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010817i · Cited by 70
Self-citationBrain iron in the ferrocene-loaded rat: Its chelation and influence on dopamine metabolism
Ward, R. J., Dexter, D. T., Florence, A., Aouad, F., Hider, R. C., Jenner, P. G., & Crichton, R. R. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00521-m · Cited by 68
Self-citationHabgood, M. D., Liu, Z. D., Saghaei, L., Khodr, H., Abbott, J., & Hider, R. C. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00031-3 · Cited by 67
Self-citationActive transport of siderophore-mimicking antibacterials across the outer membrane
Braun, V. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0107 · Cited by 66
HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy
Bergeron, R. J., Wiegand, J., & Brittenham, G. M. (1998) · Blood · doi:10.1182/blood.v91.4.1446 · Cited by 66
Intensive Iron-Chelation Therapy with Desferrioxamine in Iron-Loading Anaemias
Pippard, M. J., Callender, S. T., & Weatherall, D. J. (1978) · Clinical Science · doi:10.1042/cs0540099 · Cited by 65
The neurotoxicity of the halogenated hydroxyquinolines. A commentary
Gp, O. (1973) · JAMA · doi:10.1001/jama.225.4.395 · Cited by 64
Kruck, T. P. A., Cui, J.-G., Percy, M. E., & Lukiw, W. J. (2004) · Cellular and Molecular Neurobiology · doi:10.1023/b:cemn.0000022773.70722.b2 · Cited by 58
Clarke, E. T., Martell, A. E., & Reibenspies, J. H. (1992) · Inorganica Chimica Acta · doi:10.1016/s0020-1693(00)86121-6 · Cited by 57
Bergeron, R. J., Wiegand, J., McManis, J. S., McCosar, B. H., Weimar, W. R., Brittenham, G. M., & Smith, R. E. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990058s · Cited by 57
Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators
Bergeron, R. J., Wiegand, J., Weimar, W. R., Vinson, J. R. T., Bussenius, J., Yao, G. W., & McManis, J. S. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980340j · Cited by 57
Gibbs, J. E., & Thomas, S. A. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00711.x · Cited by 56
New Considerations in the Treatment of Sickle Cell Disease
Reed, W., & Vichinsky, E. P. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.461 · Cited by 56
Design of clinically useful macromolecular iron chelators
Zhou, T., Winkelmann, G., Dai, Z., & Hider, R. C. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01291.x · Cited by 56
Self-citationEsters and lactones of phenolic amino carboxylic acids. Prodrugs for iron chelation
Pitt, C. G., Bao, Y., Thompson, J., Wani, M. C., Rosenkrantz, H., & Metterville, J. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00157a020 · Cited by 54
Lai, M. E., Grady, R. W., Vacquer, S., Pepe, A., Carta, M. P., Bina, P., Sau, F., Cianciulli, P., Maggio, A., Galanello, R., et al. (2010) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2010.05.005 · Cited by 51
Porter, J. B., Abeysinghe, R. D., Hoyes, K. P., Barra, C., Huehns, E. R., Brooks, P. N., Blackwell, M. P., Araneta, M., Brittenham, G., Singh, S., et al. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb08660.x · Cited by 50
Self-citationDiarra, M. S., Lavoie, M. C., Jacques, M., Darwish, I., Dolence, E. K., Dolence, J. A., Ghosh, A., Ghosh, M., Miller, M. J., & Malouin, F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.11.2610 · Cited by 50
Fernandes, S. S., Nunes, A., Gomes, A. C., de Castro, B., Hider, R. C., Rangel, M., Appelberg, R., & Gomes, M. S. (2010) · Microbes and Infection · doi:10.1016/j.micinf.2010.01.003 · Cited by 49
Self-citationGaeta, A., Molina‐Holgado, F., Kong, X. L., Salvage, S., Fakih, S., Francis, P. T., Williams, R. J., & Hider, R. C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.007 · Cited by 48
Self-citationHershko, C., Grady, R. W., & Cerami, A. (1978) · PubMed · Cited by 45
Development of iron chelators for Cooley's anemia
Martell, A. E., Motekaitis, R. J., Murase, I., Sala, L. F., Stoldt, R., Ng, C. Y., Rosenkrantz, H., & Metterville, J. J. (1987) · Inorganica Chimica Acta · doi:10.1016/s0020-1693(00)81225-6 · Cited by 45
Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin‐bound iron
Hider, R. C., Silva, A. M. N., Podinovskaia, M., & Ma, Y. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05573.x · Cited by 43
Self-citationHahn, F. E., McMurry, T. J., Hugi, A., & Raymond, K. N. (1990) · Journal of the American Chemical Society · doi:10.1021/ja00161a032 · Cited by 43
Bernier, G., Girijavallabhan, V., Murray, A., Niyaz, N., Ding, P., Miller, M. J., & Malouin, F. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.241-248.2005 · Cited by 42
Therapeutic iron chelators and their potential side-effects
Singh, S., Khodr, H., Taylor, M. I., & Hider, R. C. (1995) · Biochemical Society Symposia · doi:10.1042/bss0610127 · Cited by 42
Self-citationPotential protection from toxicity by oral iron chelators
Hider, R. C. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03606-7 · Cited by 41
Self-citationXu, B., Kong, X., Zhou, T., Qiu, D.-H., Chen, Y., Liu, M.-S., Yang, R., & Hider, R. C. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.097 · Cited by 41
Self-citationRienhoff, H. Y., Viprakasit, V., Tay, L. H., Harmatz, P., Vichinsky, E. P., Chirnomas, D., Kwiatkowski, J. L., Tapper, A. E., Kramer, W. G., Porter, J. B., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.034405 · Cited by 40
The Fenton Activity of Iron(III) in the Presence of Deferiprone
Ld, D., Neubert, H., & Hider, R. C. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21039 · Cited by 39
Self-citationIron chelation beyond transfusion iron overload
Pietrangelo, A. (2007) · American Journal of Hematology · doi:10.1002/ajh.21101 · Cited by 38
Hershko, C., Cappellini, M. D., Galanello, R., Piga, A., Tognoni, G., & Masera, G. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04946.x · Cited by 38
Results from a Phase I Clinical Trial of HBED
Grady, R. W., Hilgartner, M. W., Giardina, P. J., & Salbe, A. D. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2554-7_37 · Cited by 36
Merkofer, M., Kissner, R., Hider, R. C., & Koppenol, W. H. (2004) · Helvetica Chimica Acta · doi:10.1002/hlca.200490272 · Cited by 35
Self-citationBergan, T., Bergan, T., Klaveness, J., Klaveness, J., Aasen, A. J., & Aasen, A. J. (2001) · Chemotherapy · doi:10.1159/000048495 · Cited by 34
Synthesis of feralex a novel aluminum/iron chelating compound
Kruck, T. P. A., & Burrow, T. E. (2002) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(01)00372-5 · Cited by 32
Amido‐3‐hydroxypyridin‐4‐ones as Iron(III) Ligands
Piyamongkol, S., Yong, M. A. O., Kong, X. L., Liu, Z. D., Aytemir, M. D., der Helm, D. V., & Hider, R. C. (2010) · Chemistry - A European Journal · doi:10.1002/chem.200902455 · Cited by 32
Self-citationWeiss, H., Fresneau, M., Camenisch, G., Kretz, O., & Groß, G. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006429 · Cited by 32
Is the β thalassaemia trait of clinical importance?
Premawardhena, A., Arambepola, M., Katugaha, N., & Weatherall, D. J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07071.x · Cited by 31
Synthesis of N,N′-di(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid (HBED) and derivatives
Martell, A. E., Motekaitis, R. J., Clarke, E. T., & Harrison, J. J. (1986) · Canadian Journal of Chemistry · doi:10.1139/v86-070 · Cited by 28
Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy
Ld, D., Evans, R. W., Evans, P., & Hider, R. C. (2007) · Biochemical Journal · doi:10.1042/bj20070823 · Cited by 28
Self-citationFaller, B., Spanka, C., Sergejew, T., & Tschinke, V. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990261n · Cited by 27
Bergeron, R. J., Wiegand, J., Bharti, N., McManis, J. S., & Singh, S. P. (2010) · BioMetals · doi:10.1007/s10534-010-9389-y · Cited by 27
Kim, M. (1996) · Journal of Nutrition · doi:10.1093/jn/126.9.2172 · Cited by 25
A Possible Mode of Action of Some Anti-Fungal and Anti-Bacterial Chelating Agents
LOWE, M. B., & Phillips, J. N. (1962) · Nature · doi:10.1038/1941058a0 · Cited by 25
In Vitro Growth Inhibition of Mastitis Causing Bacteria by Phenolics and Metal Chelators
Chew, B. P., Tjoelker, L. W., & Tanaka, T. (1985) · Journal of Dairy Science · doi:10.3168/jds.s0022-0302(85)81199-1 · Cited by 22
DTPA in the management of iron overload in thalassaemia
Jackson, M. J., Brenton, D. P., & Modell, B. (1983) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01810345 · Cited by 20
Yokel, R. A., Fredenburg, A. M., Meurer, K. A., & Skinner, T. L. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06763-7 · Cited by 20
Bergeron, R. J., Wiegand, J., McManis, J. S., Vinson, J. R. T., Yao, H., Bharti, N., & Rocca, J. R. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0508944 · Cited by 19
Charge States of Deferasirox–Ferric Iron Complexes
Hider, R. C. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.10.065 · Cited by 16
Self-citationMoridani, M. Y., Tilbrook, G. S., Khodr, H., & Hider, R. C. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778592 · Cited by 15
Self-citationLowther, N., Fox, R., Faller, B., Nick, H., Jin, Y., Sergejew, T., Hirschberg, Y., Oberle, R. L., & Donnelly, H. (1999) · Pharmaceutical Research · doi:10.1023/a:1018886005136 · Cited by 15
Lowther, N., Tomlinson, B., Fox, R., Faller, B., Sergejew, T., & Donnelly, H. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980191s · Cited by 14
Biliary and Urinary Metabolic Profiles of 1,2-Diethyl-3-hydroxypyridin-4-one (CP94) in the Rat
Lu, S. L., Gosriwatana, I., Liu, D. Y., Liu, Z. D., Mallet, A. I., & Hider, R. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15157-4 · Cited by 13
Self-citationDesign and synthesis of fluorine-substituted 3-hydroxypyridin-4-ones
Min, Y. K., & Hider, R. C. (2010) · Tetrahedron Letters · doi:10.1016/j.tetlet.2010.07.134 · Cited by 13
Self-citation
Research works printed but not linked: 11
- Pearson, 1963, J. Am. Chem. Soc., 85, 3535
- Thieken, 1992, FEMS Microbiol. Lett., 94, 37, 10.1111/j.1574-6968.1992.tb05285.x · doi:10.1111/j.1574-6968.1992.tb05285.x · Paper page
- Holander, 1988, Can. J. Gastroenterol., 2, 35A
- Hider, 1992, Proc. R. Soc. Edinburgh, 99B, 137
- Hershko, 1978, J. Lab. Clin. Med., 92, 144
- Pippard, 1978, Clin. Sci. Mol. Med., 54, 99
- Wolfe, 1990, Semin. Hematol., 27, 117
- Galanello, 2003, J. Clin. Pharmacol., 43, 565, 10.1177/0091270003253350 · doi:10.1177/0091270003253350 · Paper page
- Piga, 2003, J. Hematol., 88, 489
- Oakley, 1973, JAMA, J. Am. Med. Assoc., 225, 395, 10.1001/jama.1973.03220310031006 · doi:10.1001/jama.1973.03220310031006
- Albert, 1947, Br. J. Exp. Path., 28, 69
Cited by
Nutritional immunity: transition metals at the pathogen–host interface
Hood, M. I., & Skaar, E. P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2836 · Cited by 1,535
Iron homeostasis in host defence and inflammation
Ganz, T., & Nemeth, E. (2015) · Nature Reviews Immunology · doi:10.1038/nri3863 · Cited by 843
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Jack of all trades: versatile catechol crosslinking mechanisms
Yang, J., Cohen Stuart, M. A., & Kamperman, M. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00185k · Cited by 702
Singh, N., Haldar, S., Tripathi, A. K., Horback, K., Wong, J., Sharma, D., Beserra, A., Suda, S., Anbalagan, C., Dev, S., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4931 · Cited by 208
“Some studies suggest that an iron chelator should have good oral bioavailability and have even smaller size ( < 300Da); however, the main delivery methods with proven effectiveness so far have been through the intra-venous route (483).”
Metadata
- Authors
- Zhou, T., Ma, Y., Kong, X., & Hider, R. C.
- Affiliations
- Zhejiang Gongshang University (CN)
- King's College London (GB)
- Corresponding author
- Hider, Robert C.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 41
- Issue
- 21
- Pages
- 6371
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2028066320
- Cited by
- 136
- References
- 142
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 10 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 14 · 2017: 13 · 2016: 7 · 2015: 12 · 2014: 11 · 2013: 15 · 2012: 5
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Dalton Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- iron chelators, chelation therapy, iron overload, beta-thalassaemia major, sickle cell disease, neurodegenerative diseases, microbial infection, drug design, iron toxicity
- MeSH terms
- Anti-Bacterial Agents, Humans, Iron Chelating Agents, Drug Design, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.